• Alden, C. L., R. D. Parker & D. F. Eastman: Development of an acute model for the study of chloromethanediphosphonate nephrotoxicity. Toxicol. Pathol. 1989, 17, 2732.
  • Alden, C. L., J. L. Burns, R. D. Parker, J. L. Englehart & V. W. Dennis: Characterization of the early ultrastructural and biochemical events occurring in dichloromethane diphosphonate nephrotoxicity. Toxicol. Pathol. 1990, 18, 661666.
  • Bisaz, S., A. Jung & H. Fleisch: Uptake by bone of pyrophosphate, diphosphonates and their technetium derivatives. Clin. Sci. Mol. Med. 1978, 54, 265272.
  • Bounameaux, H. M., J. Schifferli, J. P. Montani, A. Jung & F. Chatelanat: Renal failure associated with intravenous diphosphonates. Lancet 1983, I, 471.
  • Dumon, J. C., A. Magritte & J. J. Body: Efficacy and safety of the bisphosphonate tiludronate for the treatment of tumor-associated hypercalcemia. Bone Miner. 1991, 15, 257266.
  • Fent, K., E. Mayer & G. Zbinden: Nephrotoxicity screening in rats: a validation study. Arch. Toxicol. 1988, 61, 349358.
  • Fitton, A. & D. McTavish: Pamidronate: a review of its pharmacological and therapeutic efficacy in resorptive bone disease. Drugs 1991, 41, 289318.
  • Fleisch, H. Bisphosphonates in bone disease: from the laboratory to the patient. Parthenon Publishing Group Ltd., New York & London, 1995.
  • Grabenstetter, R. J. & W. A. Cilley: Polynuclear complex formation in solutions of calcium ion and ethane-1-hydroxy-1,1-diphosphonic acid. I. Complexometric and pH titrations. J. Phys. Chem. 1971, 75, 672682.
  • Green, J. R., K. Müller & K. A. Jaeggi: Preclinical pharmacology of CGP 42 446, a new, potent, heterocyclic bisphosphonate compound. J. Bone Miner. Res. 1994, 9, 745751.
  • Kanis, J. A., C. J. Preston, A. J. P. Yates, R. C. Percival, K. I. Mundy & R. G. G. Russell: Effects of intravenous diphosphonates on renal function. Lancet 1983, I, 1328.
  • Kanis, J. A., G. H. Urwin, R. E. S. Gray, M. N. C. Beneton, E. V. McCloskey, N. A. T. Hamdy & S. A. Murray: Effects of intravenous etidronate disodium on skeletal and calcium metabolism. Amer. J. Med. 1987, 82, suppl. 2A, 5570.
  • Mian, M., F. Beghé, A. Caprio, R. Aloj & A. Bertelli: Tolerability and safety of clodronate therapy in bone diseases. Int. J. Clin. Pharm. Res. 1991, 11, 107114.
  • Russell, R. G. G., R. C. Mühlbauer, S. Bisaz, D. A. Williams & H. Fleisch: The influence of pyrophosphate, condensed phosphates, phosphonates and other phosphate compounds on the dissolution of hydroxyapatite in vitro and on bone resorption induced by parathyroid hormone in tissue culture and in thyroparathyro-idectomised rats. Calcif. Tissue Res. 1970, 6, 183189.
  • Schaffer, A. V., H. Buckler, W. Ryan & P. Richardson: A double blind placebo-controlled trial using intravenous zoledronate (CGP 42446) in patients with Paget's disease of bone. J. Bone Miner. Res. 1996, 11, suppl. 1, S373.
  • Troehler, U., J. P. Bonjour & H. Fleisch: Renal secretion of diphosphonates in rats. Kidney Int. 1975, 8, 613.
  • Wiers, B. H.: Polynuclear complex formation in solutions of calcium ion and ethane-1-hydroxy-1,1-diphosphonic acid. II. Light scattering, sedimentation, mobility, and dialysis measurements. J. Phys. Chem. 1971, 75, 682687.
  • Yates, A. J. P., R. E. S. Gray, G. H. Urwin, C. J. Preston, R. G. G. Russell, R. C. Percival, R. M. Atkins, N. A. T. Hamdy, M. N. C. Beneton & J. A. Kanis: Intravenous clodronate in the treatment and retreatment of Paget's disease of bone. Lancet 1985, I, 14741477.
  • Zbinden, G., K. Fent & M. H. Thouin: Nephrotoxicity screening in rats; general approach and establishment of test criteria. Arch. Toxicol. 1988, 61, 344348.